Japan: are statins still good for everybody?

Lancet

Volumn 368, Issue 9542, 2006, Pages 1135-1136

  Sirtori, Cesare R ^a,b   Calabresi, Laura ^a,b  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

ARTICLE; BRAIN ISCHEMIA; CLINICAL TRIAL; DIABETES MELLITUS; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; JAPAN; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION;

EID: 33748979729     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69450-6     Document Type: Note

References (12)

1. Cholesterol Treatment Trialist (CCT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
2. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet 363 (2004) 757-767
3. Colhoun H., Betteridge D., Durrington P., and on behalf of the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
4. Howard B., Best L., Galloway J., et al. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care 29 (2006) 391-397
5. Walsh J., and Pignone M. Drug treatment of hyperlipidemia in women. JAMA 291 (2004) 2243-2252
6. Nakamura H., Arakawa K., Itakura H., et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368 (2006) 1155-1163
7. Sirtori C. The FIELD study. Lancet 367 (2006) 1141-1142
8. Sirtori C., Calabresi L., Marchioli R., and Rubins H. Cardiovascular risk changes after lipid lowering medications: are they predictable?. Atherosclerosis 152 (2000) 1-8
9. Opie L., Commerford P., and Gersh B. Controversies in stable coronary artery disease. Lancet 367 (2006) 69-78
10. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
11. Bruckert E., Hayem G., Dejager S., Yau C., and Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 19 (2005) 403-414
12. Iwata H., Matsuo K., Hara S., et al. Use of hydroxy-methyl-glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies. Cancer Sci 97 (2006) 133-138